Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of MYO-029 in Adult Muscular Dystrophy Patients
2004-000622-67Phase 2Completed
- Sponsor
- Wyeth
- Start
- Feb 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Becker muscular dystrophy (BMD), facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) comparing MYO-029 multiple ascending dose with Placebo (2 arms). Primary endpoint: Primary safety assessment. Started Feb 2005; status: completed.
02
Drugs
stamulumab
03
Conditions
Becker muscular dystrophy (BMD)facioscapulohumeral muscular dystrophy (FSHD)limb-girdle muscular dystrophy (LGMD)
Beyond the preview
Go deeper on 2004-000622-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000622-67.